Anti-IDH1 R132H (Hu) aus Maus (Klon: H09)

482,00 

500 µl

Voraussichtliche Lieferzeit: 1 Werktag

Artikelnummer: DIA-H09 Kategorien: , , Schlüsselworte: , ,
  • Übersicht
    Spezifität

    Spezies-Reaktivität

    Wirtsspezies

    Isotyp

    Klon

    Klonalität (Mono-/Polyklonal)

    Anwendung

    , ,

    Verdünnung

    Format

    ,

    Produktlinie / Thema

    ,

    Zweckbestimmung

    Temperatur - Lagerung

    Suchcode

    ,

    Hersteller / Marke

  • Datenblätter
  • Weitere Produktinformationen
    Background

    Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.

    Combined immunohistochemistry of ATRX (dianova clone AX1) and IDH1R132H (dianova clone H09)
    substitutes molecular testing.

    The routine practical approach for diagnosing astrocytomas and oligodendrogliomas begins with perfoming IHC for IDH1 R132H and ATRX expression. Stepwise analysis of molecular parameters with initial IHC for ATRX and IDH1 R132H followed by 1p/19q analysis and then by IDH sequencing significantly reduces the number of molecular tests required for unequivocal diagnosis (Reuss et al., 2015). Learn more…

    Comparative study
    References
    1. Capper D et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118(5): 599-601, 2009
    2. Capper D et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20(1): 245-254, 2010
    3. Preusser M et al. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clinical Neuropathology, 30(5):217-230, 2011
    4. Van den Bent MJ et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173–178, 2013
    5. Schumacher T et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, DOI:10.1038/nature13387
    6. Reuss DE et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an „integrated“ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 129(1):133-146, 2015
    7. David NL et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol., 131:803-820, 2016
  • Bilder
    IDH1-R132H-infiltration-zone-glioma
    IDH1-R132H-infiltration-zone-glioma
    IDH1-R132H-Cortex-infiltrated-by-oligodendroglioma
    IDH1-R132H-Cortex-infiltrated-by-oligodendroglioma
    IDH1-R132H-Double-staining-of-GFP-and-clone-H09
    IDH1-R132H-Double-staining-of-GFP-and-clone-H09
    IDH1-R132H-Identification-of-single-tumor-cells
    IDH1-R132H-Identification-of-single-tumor-cells
    IDH1-R132H-infiltrating-glioma-cells
    IDH1-R132H-infiltrating-glioma-cells
    IDH1-R132H-strong-reaction-on-mutated-diffuse-astrocytoma
    IDH1-R132H-strong-reaction-on-mutated-diffuse-astrocytoma
    IDH1-R132H-tumor-center-of-anaplastic-oligoastrocytoma.
    IDH1-R132H-tumor-center-of-anaplastic-oligoastrocytoma.
Kontakt
Bestellung:
Tel.: +49 (0)40 / 450670
Beratung:
Tel.: +49 (0)40 / 450670